Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Researchers identify strategy for overcoming resistance to RAS-targeted cancer drugs (opens in a new tab)

medicalxpress.com · 2026-11-02

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Four of six claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 4 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredResults of the preclinical study, led by Roswell Park faculty members Vishnu Kumarasamy, Ph.D., Agnieszka Witkiewicz, M.D., and Erik Knudsen, Ph.D., were published in Cancer Research.View evidenceHide evidence

Why this verdict

The supplied paper profile does not include author/leadership metadata or journal-publication metadata beyond a document identifier. The scientific profile therefore does not verify the named Roswell Park faculty leads or publication in Cancer Research at this evidence depth.

Claim 2 of 6Not coveredCombination approaches produced more durable tumor control in laboratory and animal models than KRAS inhibition alone.View evidenceHide evidence

As statedmore durable

Why this verdict

The profile supports that CDK2 cotargeting produced a more durable cytostatic response in vitro and that concurrent KRAS plus CDK4/6 or CDK2 inhibition yielded durable tumor control in xenografts. However, the abstract-level profile does not provide enough detail to verify the story's explicit comparative claim that the combination approaches were more durable than KRAS inhibition alone across laboratory and animal models.

1

Study evidence

Cotargeting CDK2 impaired DNA replication in resistant models.

“cotargeting CDK2 exerted a broader effect by impairing DNA replication, inducing G2 arrest, preventing mitotic entry”
2

Study evidence

Concurrent inhibition of KRAS with either CDK4/6 or CDK2 yielded durable tumor control in vivo in xenografts derived from models with acquired resistance.

“concurrent inhibition of KRAS with either CDK4/6 or CDK2 yielded durable tumor control in vivo in xenografts derived from models with acquired resistance.”
Claim 3 of 6SupportedResearchers at Roswell Park Comprehensive Cancer Center have identified a promising strategy for overcoming one of the biggest challenges facing KRAS-targeted cancer therapies: treatment resistance.View evidenceHide evidence

As statedone of the biggest challenges

Why this verdict

The paper profile supports a preclinical strategy for overcoming KRAS/RAS-inhibitor resistance: resistant models sustain cell-cycle progression despite KRAS suppression, and functional screens plus xenograft work nominate CDK4/6 or CDK2 cotargeting. The headline wording is promotional, but it remains tied to a preclinical, hedged 'promising strategy' framing and does not materially outrun the body caveats.

1

Study evidence

Resistant KRAS/RAS-inhibitor models sustain cell-cycle progression despite effective suppression of mutant KRAS signaling.

“transcriptomic and proteomic analyses revealed that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell-cycle progression”
2

Study evidence

Combinatorial drug and genome-wide CRISPR–Cas9 screens pinpointed CDK4/6 and CDK2 as cell-cycle targets whose perturbation restored sensitivity to KRAS/RAS inhibitors in models with acquired resistance.

“Combinatorial drug screens ... showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
Claim 4 of 6SupportedThe researchers found that even when RAS signaling was successfully blocked, cancer cells could maintain cell proliferation by activating alternative pathways, and persistent cell-cycle activity emerged as a common feature of resistant tumors.View evidenceHide evidence

As statedcommon feature

Why this verdict

The abstract-level profile states that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell-cycle progression and engage distinct, context-dependent orthogonal mitogenic pathways to bypass KRAS inhibition. That supports the story's statement that alternative pathways and persistent cell-cycle activity are central features of resistant models.

1

Study evidence

Resistant KRAS/RAS-inhibitor models sustain cell-cycle progression despite effective suppression of mutant KRAS signaling.

“transcriptomic and proteomic analyses revealed that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell-cycle progression”
Claim 5 of 6SupportedBlocking the key cell-cycle regulators CDK4/6 or CDK2 kinases restored sensitivity to KRAS- and RAS-targeted therapies.View evidenceHide evidence

Why this verdict

The profile reports combinatorial drug screens and genome-wide CRISPR-Cas9 screens showing that perturbing CDK4/6 or CDK2 restored sensitivity to KRAS/RAS inhibitors in resistant models, with mechanistic profiling of both cotargeting approaches.

1

Study evidence

Combinatorial drug and genome-wide CRISPR–Cas9 screens pinpointed CDK4/6 and CDK2 as cell-cycle targets whose perturbation restored sensitivity to KRAS/RAS inhibitors in models with acquired resistance.

“Combinatorial drug screens ... showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
2

Study evidence

Genome-wide CRISPR–Cas9 loss-of-function screens in resistant models identified CDK4/6 and CDK2 as genetic perturbations that restore sensitivity to KRAS/RAS inhibitors.

“... and genome-wide CRISPR–Cas9 screens showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
Claim 6 of 6SupportedThe findings may help guide future clinical strategies aimed at extending the effectiveness of KRAS-targeted medicines and delaying disease progression.View evidenceHide evidence

Why this verdict

The paper profile supports a preclinical rationale for future therapeutic strategies aimed at overcoming acquired resistance to KRAS/RAS inhibition. The story uses appropriately speculative language ('may help guide future clinical strategies') and mentions the preclinical/lab/animal context, so it does not claim clinical efficacy has been shown.

1

Study evidence

Combinatorial drug and genome-wide CRISPR–Cas9 screens pinpointed CDK4/6 and CDK2 as cell-cycle targets whose perturbation restored sensitivity to KRAS/RAS inhibitors in models with acquired resistance.

“Combinatorial drug screens ... showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
2

Study evidence

Genome-wide CRISPR–Cas9 loss-of-function screens in resistant models identified CDK4/6 and CDK2 as genetic perturbations that restore sensitivity to KRAS/RAS inhibitors.

“... and genome-wide CRISPR–Cas9 screens showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Mechanistic distinction between CDK4/6 and CDK2 cotargeting: CDK4/6 induces G1 arrest/E2F suppression, while CDK2 affects DNA replication, G2 arrest, mitotic entry, and delayed outgrowth after withdrawal.

    The story mentions CDK4/6 and CDK2 as targets and generally discusses durable control, but it omits the mechanistic differences between the two cotargeting approaches.

    From in vitro; in vitro

4 things the story did carry across
  • Resistant KRAS/RAS-inhibitor cancer models sustain cell-cycle progression despite effective suppression of mutant KRAS signaling, with context-dependent bypass through orthogonal mitogenic pathways.
  • Functional screening evidence: combinatorial drug screens and genome-wide CRISPR-Cas9 screens identified CDK4/6 and CDK2 as cell-cycle nodes whose perturbation restores sensitivity to KRAS/RAS inhibitors.
  • In vivo xenograft validation showed concurrent KRAS inhibition with either CDK4/6 or CDK2 inhibition yielded durable tumor control in acquired-resistance-derived xenografts.
  • The evidence is preclinical, based on in vitro resistant models and mouse xenografts; clinical efficacy, clinical durability, and safety/tolerability of the combinations are not established in the abstract-level profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroCombinatorial functional screens (drug combination screens and genome-wide CRISPR–Cas9 screens) identify cell-cycle nodes (CDK4/6 and CDK2) whose perturbation restores sensitivity to KRAS/RAS inhibitors in resistant models.Combinatorial drug screening; genome-wide CRISPR–Cas9 loss-of-function screeningExpand

In plain English

Combinatorial drug screens and genome-wide CRISPR–Cas9 loss-of-function screens performed in resistant in vitro cancer models identified cyclin-dependent kinases CDK4/6 and CDK2 as cell-cycle nodes whose perturbation restored sensitivity to KRAS- or pan-RAS inhibitors.

Key findings

  • Combinatorial drug and genome-wide CRISPR–Cas9 screens pinpointed CDK4/6 and CDK2 as cell-cycle targets whose perturbation restored sensitivity to KRAS/RAS inhibitors in models with acquired resistance.
“Combinatorial drug screens ... showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroResistant KRAS/ RAS-inhibitor cancer models sustain cell-cycle progression despite effective suppression of mutant KRAS signaling, via context-dependent engagement of orthogonal mitogenic pathways.In vitro molecular profiling of resistant modelsExpand

In plain English

Transcriptomic and proteomic profiling of KRAS/RAS-inhibitor–resistant cancer models shows that, despite effective suppression of mutant KRAS signaling, resistant cells maintain cell-cycle progression by engaging distinct, context-dependent mitogenic bypass pathways; broad pan‑RAS-ON inhibition (RMC-6236) can suppress these pathways but cells can acquire resistance in which proliferation becomes uncoupled from RAS signaling.

Key findings

  • Resistant KRAS/RAS-inhibitor models sustain cell-cycle progression despite effective suppression of mutant KRAS signaling.
  • Distinct orthogonal mitogenic pathways are engaged in a context-dependent manner to bypass KRAS inhibition.
“transcriptomic and proteomic analyses revealed that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell-cycle progression”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3in vitroCombinatorial functional screens (drug combination screens and genome-wide CRISPR–Cas9 screens) identify cell-cycle nodes (CDK4/6 and CDK2) whose perturbation restores sensitivity to KRAS/RAS inhibitors in resistant models.Genome-wide CRISPR–Cas9 loss-of-function screenExpand

In plain English

The paper reports genome-wide CRISPR–Cas9 loss-of-function screens performed in KRAS/RAS-inhibitor–resistant models that identified cell-cycle regulatory nodes, specifically CDK4/6 and CDK2, whose genetic perturbation restored sensitivity to KRAS/RAS inhibitors.

Key findings

  • Genome-wide CRISPR–Cas9 loss-of-function screens in resistant models identified CDK4/6 and CDK2 as genetic perturbations that restore sensitivity to KRAS/RAS inhibitors.
“... and genome-wide CRISPR–Cas9 screens showed that perturbing cell-cycle nodes via targeting cyclin-dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors.”
What this piece can’t prove
  • All information is drawn from the paper abstract; methodological and numerical details of the genome-wide CRISPR–Cas9 screens are not provided there.

2 further details could not be confirmed from the summary.

4in vitroMechanistic/phenotypic profiling distinguishes CDK4/6 versus CDK2 cotargeting effects on cell-cycle state and durability of cytostasis (e.g., G1 arrest/E2F suppression vs impaired DNA replication, G2 arrest, mitotic entry prevention, delayed outgrowth after withdrawal).Expand

In plain English

In vitro mechanistic profiling reported that cotargeting KRAS/RAS inhibitors with CDK4/6 inhibition induced G1 cell-cycle arrest and suppressed E2F-regulated protein expression across resistant models.

Key findings

  • Cotargeting CDK4/6 with KRAS/RAS inhibitors produced G1 arrest and suppression of E2F-regulated proteins across resistant models.
“Cotargeting CDK4/6 induced G1 arrest and suppressed E2F-regulated proteins across all resistant models.”
What this piece can’t prove
  • Methods are described only at a high level; specific assays, reagents, and time courses are not detailed.

3 further details could not be confirmed from the summary.

5in vitroMechanistic/phenotypic profiling distinguishes CDK4/6 versus CDK2 cotargeting effects on cell-cycle state and durability of cytostasis (e.g., G1 arrest/E2F suppression vs impaired DNA replication, G2 arrest, mitotic entry prevention, delayed outgrowth after withdrawal).Expand

In plain English

In models with acquired resistance to KRAS/RAS inhibitors, cotargeting CDK2 (concurrent with KRAS/RAS inhibition) impaired DNA replication, induced G2 arrest and prevented mitotic entry, and produced a more durable cytostatic response that delayed cellular outgrowth after drug withdrawal (as reported in the abstract).

Key findings

  • Cotargeting CDK2 impaired DNA replication in resistant models.
  • Cotargeting CDK2 induced G2 arrest and prevented mitotic entry.
“cotargeting CDK2 exerted a broader effect by impairing DNA replication, inducing G2 arrest, preventing mitotic entry”
What this piece can’t prove
  • The abstract does not specify which cell lines or resistant models were used for the reported in vitro mechanistic profiling.

2 further details could not be confirmed from the summary.

6in vivo animalIn vivo validation: concurrent inhibition of KRAS with either CDK4/6 or CDK2 yields durable tumor control in xenografts derived from acquired-resistance models.in vivo xenograft efficacy studyExpand

In plain English

In mouse xenograft efficacy studies using tumors derived from models with acquired resistance to KRAS/RAS inhibitors, concurrent pharmacologic inhibition of KRAS together with either CDK4/6 or CDK2 produced durable tumor control in vivo, indicating that cotargeting cell-cycle nodes can overcome acquired resistance in these preclinical models.

Key findings

  • Concurrent inhibition of KRAS with either CDK4/6 or CDK2 yielded durable tumor control in vivo in xenografts derived from models with acquired resistance.
“concurrent inhibition of KRAS with either CDK4/6 or CDK2 yielded durable tumor control in vivo in xenografts derived from models with acquired resistance.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

Faculty Opinions recommendation of KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2018 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.